Letrozin

Letrozole, the active ingredient in Letrozin, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine therapy of hormone‑receptor positive breast cancer in postmenopausal women, where it reduces estrogen production.

GNH USA supplies Letrozin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. All batches are manufactured under EU GMP standards and undergo rigorous quality testing before release. The product is distributed through a secure cold‑chain logistics network to maintain integrity during international transport.

Letrozole is indicated for endocrine therapy targeting estrogen‑dependent breast cancer in postmenopausal patients.

- Hormone‑receptor positive breast cancer (postmenopausal): reduces estrogen‑driven tumor growth. - Adjuvant therapy after surgery (postmenopausal): lowers risk of disease recurrence. - Metastatic breast cancer (postmenopausal): delays disease progression.

Letrozole may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aches affecting mobility. - Fatigue: persistent tiredness. - Nausea: upset stomach and urge to vomit.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes. - Bone fracture: increased risk due to reduced bone density. - Deep vein thrombosis or pulmonary embolism: swelling, pain, shortness of breath. - Cardiovascular events: hypertension, arrhythmias.

Before initiating Letrozin, clinicians should assess several safety parameters.

- Monitor bone density: evaluate risk of osteoporosis and consider supplementation. - Evaluate liver function: check hepatic enzymes prior to and during therapy. - Assess cardiovascular risk: monitor blood pressure and lipid profile regularly. - Counsel on hot flashes and mood changes: provide supportive measures. - Store at ambient temperature: keep in original container, protect from moisture and light.

Letrozin can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce letrozole exposure. - Tamoxifen: can antagonize aromatase inhibition. - Estrogen‑containing hormone therapy: may counteract therapeutic effect.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): may increase letrozole plasma levels. - Certain SSRIs: may affect metabolism and require monitoring.